ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Anthera Pharmaceuticals Inc (CE)

Anthera Pharmaceuticals Inc (CE) (ANTH)

0,000001
0,00
(0,00%)
Fermé 05 Février 10:00PM

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

Dernier
0,000001
Prix Achat
0,00
Prix Vente
0,00
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,000001 Plage de 52 semaines 0,0002
Clôture Veille
0,000001
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
16 467
Volume financier
-
VWAP
-

ANTH Dernières nouvelles

Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the...

HAYWARD, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to...

Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura

Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”)Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”)Further...

Anthera Pharmaceuticals to Present at the 30TH Annual ROTH Conference

HAYWARD, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat...

Anthera Pharmaceuticals Deemed Compliant with Nasdaq Listing Criteria

HAYWARD, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals (Nasdaq:ANTH) today announced that Anthera has received formal notice from The NASDAQ Stock Market LLC (“Nasdaq”...

Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results

RESULT study reported positive interim futility analyses and completion of dosing, with top line data expected in March 2018Completed private placement for net proceeds of $13.3 million...

Anthera Pharmaceuticals to Participate in the BIO CEO & Investor Conference and SunTrust Robinson Humphrey’s 4th Annual Orp...

HAYWARD, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat...

Anthera Concludes Last Patient Visit in the Phase 3 RESULT Clinical Study of Sollpura

HAYWARD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) is pleased to announce that the final patient has completed the last visit in the primary...

Anthera Receives Positive Nasdaq Listing Determination

HAYWARD, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that on January 24, 2018, Anthera received formal notice that the Nasdaq...

Anthera Announces Positive Outcome of Second Interim Futility Analysis in the Phase 3 RESULT Clinical Study of Sollpura: Stud...

HAYWARD, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced a positive outcome of the second, pre-specified interim futility analysis for...

Anthera Pharmaceuticals Announces Second Closing of $15 Million Private Placement Offering

HAYWARD, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it has completed the second closing of the private placement of its equity...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1001.0E-61.0E-61.0E-614401.0E-6CS
4001.0E-61.0E-61.0E-618701.0E-6CS
12-9.9E-5-990.00010.00021.0E-6164674.389E-5CS
26001.0E-60.00021.0E-6152377.105E-5CS
52001.0E-60.00021.0E-6131586.667E-5CS
156001.0E-60.0081.0E-6148488.684E-5CS
260-0.035999-99.99722222220.0360.1891.0E-6886360.04112904CS

ANTH - Frequently Asked Questions (FAQ)

What is the current Anthera Pharmaceuticals (CE) share price?
The current share price of Anthera Pharmaceuticals (CE) is US$ 0,000001
What is the 1 year trading range for Anthera Pharmaceuticals (CE) share price?
Anthera Pharmaceuticals (CE) has traded in the range of US$ 0,000001 to US$ 0,0002 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
ELIQQElectriq Power Holdings Inc (CE)
US$ 0,20
(199 900,00%)
100
THMOThermoGenesis Holdings Inc (CE)
US$ 0,0007
(69 900,00%)
462
ALKMAlkame Holdings Inc (CE)
US$ 0,0001
(9 900,00%)
100k
GRLFGreen Leaf Innovations Inc (PK)
US$ 0,0001
(9 900,00%)
340,21M
PSRUValiant Eagle Inc (PK)
US$ 0,0001
(9 900,00%)
18,05M
TTMZFDatable Technology Corporation (CE)
US$ 0,000001
(-100,00%)
1 000
VRVRVirtual Interactive Technologies Corporation (CE)
US$ 0,0005
(-99,87%)
2,4k
PKLBFPerk Labs Inc (CE)
US$ 0,000001
(-99,67%)
9k
CLVRClever Leaves Holdings Inc (CE)
US$ 0,0001
(-99,60%)
1,6k
EFTReFFECTOR Therapeutics Inc (CE)
US$ 0,000001
(-99,50%)
110
RONNRonn Motor Group Inc (PK)
US$ 0,0003
(50,00%)
360,82M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0,0001
(9 900,00%)
340,21M
PHILPHI Group Inc (PK)
US$ 0,0003
(50,00%)
260,49M
HMBLHUMBL Inc (PK)
US$ 0,0007
(7,69%)
226,69M
TKMOTekumo Inc (PK)
US$ 0,0003
(-14,29%)
185,82M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock